PubRank

C Thiede

Author PubWeight™ 80.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995 6.32
2 Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997 3.30
3 Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. Cancer Genet Cytogenet 2001 2.57
4 Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003 1.86
5 Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998 1.80
6 Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000 1.76
7 Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997 1.75
8 Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant 2000 1.72
9 Helicobacter and gastric MALT lymphoma. Gut 2002 1.66
10 Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2011 1.64
11 SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia 2013 1.50
12 Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001 1.34
13 Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J Gastroenterol 2001 1.28
14 The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 2009 1.22
15 Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000 1.22
16 Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006 1.18
17 Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2008 1.18
18 Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999 1.12
19 Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 2011 1.07
20 Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia 2006 1.06
21 Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? J Clin Oncol 1997 1.03
22 Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999 1.02
23 Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 2010 1.01
24 Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia 2006 1.01
25 Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001 0.96
26 Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. Leukemia 2013 0.95
27 Facilitated detection of oncogene mutations from exfoliated tissue material by a PNA-mediated 'enriched PCR' protocol. J Pathol 2000 0.94
28 Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007 0.94
29 Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia 2006 0.93
30 Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res 1996 0.93
31 Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol 1997 0.91
32 Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia 2005 0.90
33 Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia 2011 0.90
34 Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia 2010 0.88
35 Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003 0.88
36 Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. Gut 2006 0.88
37 Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001 0.87
38 Focal inflammatory infiltrations in gastric biopsy specimens are suggestive of Crohn's disease. Crohn's Disease Study Group, Germany. Scand J Gastroenterol 1997 0.86
39 Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2000 0.86
40 Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Transplantation 1999 0.85
41 Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine. Leukemia 2009 0.84
42 Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 2001 0.84
43 Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplant 2005 0.84
44 SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009 0.84
45 Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. Bone Marrow Transplant 2001 0.83
46 Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. Ann Hematol 2002 0.83
47 Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. Br J Cancer 1994 0.83
48 Quality assurance in RT-PCR-based BCR/ABL diagnostics--results of an interlaboratory test and a standardization approach. Leukemia 2000 0.83
49 Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001 0.82
50 bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. Eur J Cancer 1998 0.82
51 The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 1997 0.81
52 Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia. Leukemia 2010 0.81
53 Etiology and therapy of Helicobacter pylori-associated gastric lymphomas. Ann Hematol 2003 0.81
54 Molecular diagnostics in low-grade gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type after Helicobacter pylori eradication therapy. Clin Lymphoma 2001 0.80
55 Lack of point mutations in exons 11-23 of the retinoblastoma susceptibility gene RB-1 in liver metastases of colorectal carcinoma. Oncology 2000 0.80
56 Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization. Anal Chem 2001 0.79
57 Long-term follow-up of gastric MALT lymphoma after H. pylori eradication. Curr Gastroenterol Rep 2001 0.79
58 CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2004 0.79
59 Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Ann Oncol 1995 0.79
60 Class I HDAC SNP analysis in healthy donors compared to AML patients. Leukemia 2007 0.78
61 Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000 0.78
62 P53 and induction of apoptosis as a target for anticancer therapy. Leukemia 1996 0.78
63 Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci 2001 0.78
64 Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. Bone Marrow Transplant 2001 0.77
65 Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Bone Marrow Transplant 2004 0.77
66 HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34(+) measurements and timing of leukaphereses. Cytotherapy 2003 0.77
67 Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia 2006 0.77
68 Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol 2003 0.77
69 Are lymphocytic monoclonality and immunoglobulin heavy chain (IgH) rearrangement premalignant conditions in chronic gastritis? Microsc Res Tech 2001 0.76
70 Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Ann Hematol 2002 0.75
71 Reply to: 'Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity' by Kern et al. Leukemia 2011 0.75
72 Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation. Blood Cancer J 2013 0.75
73 Specificity of immunophenotyping in acute promyelocytic leukemia. Cytometry 2000 0.75
74 Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2003 0.75
75 [Studies on homologous, erythrocytic (ABO) incompatible thrombocyte transfusions with Cr 51]. Strahlentherapie Sonderb 1967 0.75
76 MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 1996 0.75
77 Simple and rapid detection of factor V Leiden by allele-specific PCR amplification. Thromb Haemost 1996 0.75
78 Pencil injury. Oral Surg Oral Med Oral Pathol 1993 0.75
79 Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia. Leukemia 2006 0.75
80 Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation. Ann Hematol 2008 0.75
81 [An unusual course of low-malignancy non-Hodgkin lymphoma of the stomach]. Z Gastroenterol 1998 0.75
82 [Comparative studies on erythrocytic (ABO) compatible and incompatible thrombocyte transfusions in humans]. Klin Wochenschr 1966 0.75
83 Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. Ann Hematol 2004 0.75